<DOC>
	<DOCNO>NCT00380718</DOCNO>
	<brief_summary>The purpose study assess efficacy toxicity pemetrexed dose tailor individual patient tolerance patient advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Chemotherapy Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis nonsmall cell lung cancer ( NSCLC ) ( Stage IIIB IV ) Patients ' NSCLC must progress follow one chemotherapy regimen palliative therapy without subsequent targeted biological therapy Disease status must measureable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Concurrent administration tumor therapy Pregnancy breast feed Serious concomitant disorder Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>